Sign in

    Catherine Okoukoni

    Research Analyst at Citizens JMP

    Catherine Okoukoni is an Analyst at Citizens JMP Securities, specializing in healthcare equity research with a particular focus on clinical-stage biopharmaceutical companies such as Altimmune. Throughout her tenure at Citizens JMP, she has contributed detailed commercial and clinical assessments for companies undergoing pivotal developmental trials, providing coverage and insight that supports investor decision making. Okoukoni began her career as a registered securities broker and analyst, maintaining active FINRA registration and compliance with relevant industry licenses. Her analytical work is recognized for its depth in clinical trial data interpretation, and she operates out of Citizens JMP’s New York office.

    Catherine Okoukoni's questions to Altimmune (ALT) leadership

    Catherine Okoukoni's questions to Altimmune (ALT) leadership • Q2 2025

    Question

    Catherine Okoukoni of Citizens JMP requested a comparison of the cT1 imaging results from the IMPACT trial with those from competitor programs, asking for specific data ranges to contextualize Altimmune's 'best-in-class' claim.

    Answer

    Chief Medical Officer Dr. M. Scott Harris provided specific figures, stating pemvidutide showed a cT1 reduction of approximately 145-148 milliseconds. He contrasted this with publicly available data for Resmetirom (around 50-60ms) and Tirzepatide (up to 107ms), reinforcing that this result is another strong indicator of the drug's anti-inflammatory and anti-fibrotic activity.

    Ask Fintool Equity Research AI

    Catherine Okoukoni's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Catherine Okoukoni's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q1 2025

    Question

    Catherine Okoukoni, on for John Wolleben, requested details on the trial design for the 9682 program, the first candidate from the NDC platform, and asked about any specific safety concerns being monitored.

    Answer

    Dr. Dana Pizzuti, Chief Medical and Development Officer, indicated that more details would be provided at the upcoming R&D Day in June. She described the initial study as a standard dose-escalation design for oncology, with additional safety parameters since it will enroll patients directly.

    Ask Fintool Equity Research AI

    Catherine Okoukoni's questions to Mirum Pharmaceuticals (MIRM) leadership

    Catherine Okoukoni's questions to Mirum Pharmaceuticals (MIRM) leadership • Q1 2025

    Question

    On behalf of Jon Walden, Catherine Okoukoni asked how the PFIC launch in the U.S. and ex-U.S. is performing against expectations. She also inquired about the sustainability of the company's profitability into 2026.

    Answer

    CEO Christopher Peetz described the PFIC launch as 'quite a bit better than expectations,' crediting the team's execution and compelling Phase III data. CFO Eric Bjerkholt clarified that while the company was cash flow positive in Q1 and expects to be for the full year, GAAP profitability is not expected 'anytime soon' due to significant noncash charges.

    Ask Fintool Equity Research AI

    Catherine Okoukoni's questions to MADRIGAL PHARMACEUTICALS (MDGL) leadership

    Catherine Okoukoni's questions to MADRIGAL PHARMACEUTICALS (MDGL) leadership • Q4 2024

    Question

    Catherine Okoukoni from Citizens JMP asked for specifics on the 2-year open-label F4 data, including whether patients required dose adjustments and what the patient retention rate was over the two-year period.

    Answer

    Dr. Michael Charlton, Head of Clinical Development, clarified that 122 patients entered the second year of the study, with the presented data coming from 101 patients who completed a second VCTE scan. He also confirmed patients were on the 80-milligram dose.

    Ask Fintool Equity Research AI